MacroGenics, Inc. (MGNX) Reaches $20.53 After 9.00% Up Move; Aureus Asset Management Has Boosted Cedar Fair LP Depositry Unit (FUN) Holding

January 14, 2018 - By Vivian Park

Aureus Asset Management Llc increased Cedar Fair LP Depositry Unit (FUN) stake by 6.38% reported in 2017Q3 SEC filing. Aureus Asset Management Llc acquired 14,123 shares as Cedar Fair LP Depositry Unit (FUN)’s stock rose 6.08%. The Aureus Asset Management Llc holds 235,369 shares with $15.09 million value, up from 221,246 last quarter. Cedar Fair LP Depositry Unit now has $3.63 billion valuation. The stock increased 0.20% or $0.13 during the last trading session, reaching $64.5. About 145,249 shares traded or 39.32% up from the average. Cedar Fair, L.P. (NYSE:FUN) has risen 22.21% since January 14, 2017 and is uptrending. It has outperformed by 5.51% the S&P500.

The stock of MacroGenics, Inc. (NASDAQ:MGNX) is a huge mover today! The stock increased 5.55% or $1.08 during the last trading session, reaching $20.53. About 354,983 shares traded or 19.99% up from the average. MacroGenics, Inc. (NASDAQ:MGNX) has declined 9.76% since January 14, 2017 and is downtrending. It has underperformed by 26.46% the S&P500.The move comes after 8 months positive chart setup for the $755.97 million company. It was reported on Jan, 14 by Barchart.com. We have $22.38 PT which if reached, will make NASDAQ:MGNX worth $68.04M more.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $755.97 million. The company??s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

Among 10 analysts covering MacroGenics (NASDAQ:MGNX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. MacroGenics had 20 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Equal-Weight” on Monday, August 7. On Thursday, August 4 the stock rating was downgraded by Citigroup to “Neutral”. The company was maintained on Wednesday, October 25 by Leerink Swann. The firm earned “Buy” rating on Thursday, August 6 by Stifel Nicolaus. The firm has “Buy” rating given on Monday, October 19 by Citigroup. The stock of MacroGenics, Inc. (NASDAQ:MGNX) earned “Buy” rating by SunTrust on Friday, September 1. The firm has “Equal-Weight” rating given on Thursday, February 25 by Morgan Stanley. The rating was maintained by Citigroup on Friday, November 10 with “Neutral”. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Buy” rating given on Monday, September 11 by Stifel Nicolaus. Citigroup initiated it with “Neutral” rating and $31 target in Thursday, September 17 report.

Since October 25, 2017, it had 0 insider purchases, and 1 insider sale for $200,000 activity. Shares for $200,000 were sold by Wigginton Jon Marc.

Analysts await MacroGenics, Inc. (NASDAQ:MGNX) to report earnings on February, 27. They expect $2.58 EPS, up 358.00% or $3.58 from last year’s $-1 per share. MGNX’s profit will be $95.00M for 1.99 P/E if the $2.58 EPS becomes a reality. After $-1.28 actual EPS reported by MacroGenics, Inc. for the previous quarter, Wall Street now forecasts -301.56% EPS growth.

Investors sentiment decreased to 1.58 in 2017 Q3. Its down 0.15, from 1.73 in 2017Q2. It fall, as 7 investors sold MacroGenics, Inc. shares while 26 reduced holdings. 11 funds opened positions while 41 raised stakes. 27.72 million shares or 0.96% more from 27.45 million shares in 2017Q2 were reported. Voya Ltd Liability accumulated 503,145 shares or 0.02% of the stock. Rock Springs L P stated it has 0.19% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). Geode Capital Mngmt Ltd Liability Com holds 295,687 shares. Royal Bancorporation Of Canada stated it has 3,847 shares or 0% of all its holdings. Sphera Funds Management Ltd reported 208,700 shares. Renaissance Tech Limited Company holds 193,623 shares or 0% of its portfolio. Bnp Paribas Arbitrage stated it has 0% in MacroGenics, Inc. (NASDAQ:MGNX). Jacobs Levy Equity Mngmt Inc owns 0.03% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 73,551 shares. Evercore Wealth Mgmt Ltd Liability invested in 17,543 shares or 0.01% of the stock. The New York-based Tiger Limited Liability Com has invested 0.8% in MacroGenics, Inc. (NASDAQ:MGNX). Morgan Stanley reported 74,189 shares or 0% of all its holdings. Aqr Capital Mngmt Limited Liability has 54,742 shares. Emerald Mutual Fund Advisers Tru invested in 0.28% or 358,161 shares. Barclays Public Lc has 1,029 shares for 0% of their portfolio. Blackrock reported 2.69M shares.

Among 10 analysts covering Cedar Fair (NYSE:FUN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Cedar Fair had 21 analyst reports since August 24, 2015 according to SRatingsIntel. Goldman Sachs upgraded Cedar Fair, L.P. (NYSE:FUN) on Monday, January 25 to “Conviction Buy” rating. The stock of Cedar Fair, L.P. (NYSE:FUN) has “Equal-Weight” rating given on Tuesday, April 19 by Stephens. The firm has “Buy” rating given on Wednesday, September 16 by Janney Capital. Goldman Sachs upgraded the shares of FUN in report on Monday, June 19 to “Buy” rating. The rating was maintained by Stifel Nicolaus on Thursday, November 2 with “Buy”. FBR Capital maintained the stock with “Outperform” rating in Thursday, February 16 report. The rating was initiated by Macquarie Research on Wednesday, December 9 with “Neutral”. The rating was maintained by Stifel Nicolaus on Thursday, September 7 with “Buy”. The firm has “Outperform” rating given on Thursday, February 18 by FBR Capital. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, August 2.

Since August 24, 2017, it had 0 buys, and 3 insider sales for $737,660 activity. Ouimet Matthew A sold 2,000 shares worth $129,800.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: